Please assess the completion status of the following clinical trial:

Trial Title: Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe peanut and/or egg and/or milk and/or tree nut and/or seed allergic subjects between the ages of 4 to 55 years old.~* Sensitivity to food allergen will be documented by a positive skin prick test result or allergen-specific ImmunoCAP IgE level, with 7 kU/L as a lower limit of eligibility.~Exclusion Criteria:~* No absolute contraindications are known. However, the risk of serious systemic anaphylactic reactions to food allergens suggests a number of preexisting conditions that should be considered relative contraindications. Among those conditions are acute infections, autoimmune disease, severe cardiac disease, and treatment with beta-adrenergic antagonistic drugs (beta-blockers).~* Subjects with a total IgE at screening of \>2,000 kU/L~* Previous reaction to omalizumab~* Subjects having a history of severe anaphylaxis to food allergens that will be desensitized in this study requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- One (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).